Business Context and Reporting Period
This Form 8-K Current Report was filed by CytoSorbents Corporation on June 14, 2018, covering events occurring on June 12, 2018. The filing reports a significant operational milestone regarding the Company's manufacturing capabilities.
Key Financial Metrics
This filing is a Current Report (Item 8.01 Other Events) and does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The primary material event reported is the receipt of regulatory approval to commence production of the Company's product, CytoSorb, at its new manufacturing facility located in Monmouth Junction, New Jersey. This production is authorized under the Company's ISO 13485:2003 certificate.
Outlook, Risks, and Management Commentary
Management, represented by President and CEO Dr. Phillip P. Chan, highlighted the regulatory approval as a key step in scaling operations. The filing references a press release (Exhibit 99.1) for full details but does not explicitly list new risks, contingencies, or unusual items within the body of this specific report. No forward-looking financial guidance is provided in this document.
Investor Verification Checklist
- Verify the full text of the press release filed as Exhibit 99.1 for detailed production timelines.
- Confirm the operational status and capacity of the new Monmouth Junction, New Jersey facility.
- Review the Company's most recent 10-K or 10-Q filings for current financial health and liquidity status, as this 8-K contains no financial data.
- Monitor subsequent filings for updates on the volume of CytoSorb production and commercialization progress.